The COVID Heart - One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks Published March 2, 2022: JAMA doi: 10.1001/jama.2022.2411
Learn More
Long-term cardiovascular outcomes of COVID-19 Published Feb. 7, 2022: Nature Medecine https://doi.org/10.1038/s41591-022-01689-3
Learn More
Pulmonary arterial hypertension (PAH) is a rare, life-threatening condition characterized by elevated blood pressure in the arteries which carry blood from the heart to the lungs. The high blood...
Learn More
Imagine a world where a host of diseases and conditions caused by non-beneficial instructions from our DNA could be treated simply by instructing our cells to ignore those signals. That science is...
Learn More
Health Matters February 2: Calgary company Resverlogix has developed a drug that could not only stop COVID-19 illness from progressing, it also has potential to prevent chronic symptoms, or long...
Learn More
Calgary-based biotech company Resverlogix moves into a phase two clinical trial for an oral treatment Apabetalone for COVID-19. And they are looking for patients to participate in the study....
Learn More
New drug trial to treat COVID-19 patients has been launched at the University of Alberta. Hiba Kamal-Choufi reports.
Learn More
Trials for a Canadian-developed COVID-19 treatment are set to begin at the University of Alberta. CTV News Edmonton - Aired January 24, 2022
Learn More
J'lyn Nye interviews RVX President & CEO Donald McCaffrey about our Phase 2b COVID-19 Clinical Trial on 630 CHED
Learn More
By Kellen Taniguchi Edmonton Journal, January 18, 2022
Learn More
Drug developers are sourcing novel structures, bridging transcriptional and signaling domains, and exploring applications beyond oncology GEN: Genetic Engineering and Biotechnology News...
Learn More
Resverlogix is in active discussions for COVID-19 clinical studies in Morocco involving apabetalone.
Learn More
Resverlogix President & CEO Donald McCaffrey presents at Benzinga All Access conference 2021
Learn More
Clip of Donald McCaffrey, President & CEO of Resverlogix which aired on Fox News December 18, 2021. © 2021 www.B-TV.com . All Rights Reserved.
Learn More
Resverlogix reported that its lead drug apabetalone met its primary endpoint in a pulmonary arterial hypertension or ‘PAH’ investigator led pilot study. Watch the news...
Learn More
Rohit Sood, EVP, COMPLETE Commercialization, EVERSANA / Donald McCaffrey, President & CEO, Resverlogix: Next Generation Commercial Innovation: Moving From Promise to Practice.
Learn More
Donald McCaffrey, President & CEO of Resverlogix featured on Innovators with Jane King. Latest updates on the Company's COVID-19 program.
Learn More
CEO Donald McCaffrey joined PBA à Noon, for a live webinar and Q&A, to discuss the latest developments in Resverlogix' COVID-19 program.
Learn More
Resverlogix receives "No Objection Letter" from Health Canada, approving the COVID-19 Clinical Trial Application for apabetalone.
Learn More
COVID-19 affects not only lung and respiratory tissue but can injure your heart as well. One study, published in the Journal of the American Medical Association, found that 78% of recently...
Learn More
Kidneys are the body’s filtration system . They clean our blood, removing waste and helping manage blood pressure by controlling the outflow of water. Unfortunately, when these filters...
Learn More
Cardiovascular disease literally means disease of the heart and blood vessels, but it can cause additional life-altering complications that we might not initially associate with the disease,...
Learn More
This is the final article of the mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men...
Learn More
This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...
Learn More
This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...
Learn More
This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...
Learn More
This article is part of a mini-series we are calling The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of...
Learn More
Our lead compound – apabetalone – is the first small molecule of its kind with potentially important benefits for patients with high-risk cardiovascular and other chronic diseases. But...
Learn More
Resverlogix’s Dr. Ewelina Kulikowski, Senior Vice President, R&D, has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.” The article focuses on how BET inhibition has an impact on multiple biologies with the potential to treat a variety of conditions such as cancer, inflammatory, neurodegenerative, metabolic and cardiovascular disorders.
You can read “New Direction,” by Dr. Kulikowski HERE.
